SpringerLink
Log in

Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer

  • Brief Communication
  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Background

The assessment of health-related quality of life (HRQL) for patients with hormone-refractory prostate cancer (HRPC) is of paramount importance because new treatments have a modest impact on survival but side effects of treatment and disease symptoms can significantly impact HRQL.

Methods

This was an observational, non-interventional, multi-center, multi-national cohort study of patients with metastatic HRPC. Health-related quality of life was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30), the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and the EQ-5D index. Mean changes from baseline to month 3, 6, and 9 were computed and tested using paired t-tests.

Results

FACT-P PCS, EQ-5D index and 10 of 14 EORTC domains were statistically significantly lower (P < 0.05) than the baseline scores at the 3, 6 and 9 month visits. The domains that did not reach statistical significance were cognitive functioning, insomnia, diarrhea and financial difficulties.

Conclusions

These data demonstrate that patients with metastatic HRPC experience rapid, significant deterioration in HRQL, highlighting the need for effective palliative therapy for men with HRPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Petrylak, D. P., Tangen, C. M., & Hussain, M. H., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine, 351(15), 1513–520

    Article  CAS  PubMed  Google Scholar 

  2. Tannock, I. F., de Wit, R., & Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351(15), 1502–512

    Article  CAS  PubMed  Google Scholar 

  3. Sommers, S. D., & Ramsey, S. D. (1999). A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics, 16(2), 127–40

    Article  CAS  PubMed  Google Scholar 

  4. Schellhammer, P., Cockett, A., & Boccon-Gibod, L. et al. (1997). Assessment of endpoints for clinical trials for localized prostate cancer. Urology, 49(4A Suppl), 27–8

    Article  CAS  PubMed  Google Scholar 

  5. McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990–000. (2004). Journal of the National Cancer Institute. Monographs. 33, 78–01

  6. Sandblom, G., Carlsson, P., Sennfalt, K., & Varenhorst, E. A. (2004). population-based study of pain and quality of life during the year before death in men with prostate cancer. British Journal of Cancer, 90(6), 1163–168

    Article  CAS  PubMed  Google Scholar 

  7. Litwin, M. S., Lubeck, D. P., Stoddard, M. L., Pasta, D. J., Flanders, S. C., & Henning, J. M. (2001). Quality of life before death for men with prostate cancer: Results from the CaPSURE database. Journal of Urology, 165(3), 871–75

    Article  CAS  PubMed  Google Scholar 

  8. Melmed, G. Y., Kwan, L., Reid, K., Litwin, M. S. (2002). Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology, 59(1), 103–09

    Article  PubMed  Google Scholar 

  9. Aaronson, N. K., Ahmedzai, S., & Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the Natonal Cancer Institute, 85(5), 365–76

    Article  CAS  Google Scholar 

  10. Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–28

    Article  CAS  PubMed  Google Scholar 

  11. Saad, F., Gleason, D. M., & Murray, R., et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458–468

    CAS  PubMed  Google Scholar 

  12. Rodrigues, G., Bezjak, A., & Osoba, D., et al. (2004). The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer. Quality of Life Research , 13(7), 1235–246

    Article  CAS  PubMed  Google Scholar 

  13. Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–44

    CAS  PubMed  Google Scholar 

  14. King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–67

    Article  CAS  PubMed  Google Scholar 

  15. Carducci, M. A., Nelson, J. B., Vogelzang, N. J., & Mulani, P. (2005). Determination of Clinically Meaningful Change (CMC) for FACT-P. (Paper presented at: 2005) Prostate Cancer Symposium.FL: Orlando

    Google Scholar 

  16. Sullivan, P. W., Lawrence, W. F. Jr., & Ghushchyan, V. (2005). A National Catalogue of Preference-based Scores for Chronic Conditions in the U.S. Medical Care, 43(7), 736–49

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

This research was funded by Abbott Laboratories.

Author information

Authors and Affiliations

  1. Pharmaceutical Outcomes Research Program, University of Colorado School of Pharmacy, 4200 East Ninth Avenue, Box C238, Denver, CO, 80262, USA

    Patrick W. Sullivan

  2. Abbott Laboratories, Abbott Park, IL, USA

    Parvez M. Mulani

  3. H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA

    Mayer Fishman

  4. FCS Global Project Head (Oncology), Abbott Laboratories, Abbott Park, IL, USA

    Darryl Sleep

Authors
  1. Patrick W. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Parvez M. Mulani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mayer Fishman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Darryl Sleep
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick W. Sullivan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sullivan, P.W., Mulani, P.M., Fishman, M. et al. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res 16, 571–575 (2007). https://doi.org/10.1007/s11136-006-9156-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-006-9156-2

Keywords

Search

Navigation